Evolutionary Genomics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Evolutionary Genomics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Evolutionary Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 0 | -2 | 2 | 0 |
30 Sep 22 | 0 | -3 | 2 | 0 |
30 Jun 22 | 0 | -3 | 2 | 0 |
31 Mar 22 | 0 | -3 | 2 | 0 |
31 Dec 21 | 0 | -3 | 2 | 1 |
30 Sep 21 | 0 | -4 | 2 | 0 |
30 Jun 21 | 0 | -3 | 2 | 0 |
31 Mar 21 | 0 | -2 | 1 | 0 |
31 Dec 20 | 0 | -2 | 1 | 0 |
30 Sep 20 | 0 | -1 | 1 | 0 |
30 Jun 20 | 0 | -1 | 0 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 0 | -1 | 0 | 0 |
30 Sep 19 | 0 | -1 | 0 | 0 |
30 Jun 19 | 0 | -1 | 0 | 0 |
31 Mar 19 | 0 | -1 | 0 | 0 |
31 Dec 18 | 0 | -1 | 0 | 0 |
30 Sep 18 | 0 | -1 | 0 | 1 |
30 Jun 18 | 0 | -1 | 1 | 1 |
31 Mar 18 | 0 | -1 | 1 | 1 |
31 Dec 17 | 0 | -1 | 1 | 1 |
30 Sep 17 | 0 | -2 | 1 | 1 |
30 Jun 17 | 0 | -2 | 1 | 1 |
31 Mar 17 | 0 | -2 | 1 | 1 |
31 Dec 16 | 0 | -1 | 1 | 1 |
30 Sep 16 | 0 | -1 | 0 | 1 |
30 Jun 16 | 0 | 0 | 1 | 1 |
31 Mar 16 | 0 | -1 | 0 | 1 |
31 Dec 15 | 0 | 0 | 0 | 1 |
30 Sep 15 | 0 | -1 | 1 | 0 |
30 Jun 15 | 0 | -2 | 0 | 0 |
31 Mar 15 | 0 | -1 | 1 | 0 |
31 Dec 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 1 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if FNAM has high quality earnings.
Growing Profit Margin: Insufficient data to determine if FNAM's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if FNAM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare FNAM's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if FNAM's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: FNAM has a negative Return on Equity (0%), as it is currently unprofitable.